DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Michael Chamberlin - 1 hasn't - 1 we're - 1 Chamberlin - 1 that's - 1 Erin Bakke - 1 Graham - 1 Pfizer's - 1
Top related locs:
U.S Carmel Cincinnati , Ohio Aetna New York Bengaluru Edtiting United States Bengaluru
Top related orgs:
FDA - 2 Sanofi - 2 Thomson - 2 Pediatric Associates - 1 . Centers for Disease Control - 1 Prevention - 1 Pfizer - 1 GSK - 1

Search resuls for: "Synagis"


8 mentions found


☆ New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
  + stars: | 2023-10-13 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com   time to read: +2 min
Two new immunizations promise to protect babies from respiratory syncytial virus – if people can find them. Providers are scrambling to offer Pfizer's vaccine, Abrysvo, to pregnant patients and Sanofi's monoclonal antibody, Beyfortus, to babies. Until now, the only preventative treatment was another monoclonal antibody called Synagis that's given once a month during RSV season, which generally runs from fall through spring. Sanofi's Beyfortus is a monoclonal antibody that's given directly to babies and provides them with immediate protection. "I know that [RSV]'s a threat to little babies, and so to have an opportunity to prevent illness in the first place is really exciting."
Persons: Michael Chamberlin, hasn't, we're, Chamberlin, that's, Erin Bakke, Graham Organizations: Pediatric Associates Locations: Carmel, Cincinnati , Ohio
☆ Explainer: What you need to know about RSV and the new vaccines
  + stars: | 2023-09-22 | by ( Michael Erman | ) www.reuters.com   time to read: +4 min
That Pfizer (PFE.N) shot and one developed by GSK (GSK.L) in May became the first two RSV vaccines to win U.S. approval, for use in people aged 60 and over to prevent severe illness. Still, infants and older adults have a higher risk of developing severe RSV. RSV leads to 58,000 to 80,000 hospitalizations among children under age 5, and 60,000 to 160,000 hospitalizations among adults age 65 and older each year, according to the CDC. Early data suggests that the RSV shots are protective for at least two years, but it is not yet clear how often older adults will need to be revaccinated. Can I get the RSV shot alongside my COVID and flu shots?
Persons: Pfizer's, Synagis, it's, Jeffrey Duchin, you've, Michael Erman, Bhanvi, Caroline Humer, Bill Berkrot Organizations: . Centers for Disease Control, Prevention, Pfizer, GSK, CDC, FDA, Sanofi, AstraZeneca, Infectious Diseases Society of America, CVS, Humana, Thomson Locations: U.S, Aetna, New York, Bengaluru Edtiting
☆ US FDA approves Sanofi-AstraZeneca's preventive RSV therapy for babies
  + stars: | 2023-07-17 | by ( ) www.reuters.com   time to read: +2 min
July 17 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Monday it had approved Sanofi (SASY.PA) and partner AstraZeneca's (AZN.L) antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers. The therapy, branded Beyfortus, was approved for preventing lower respiratory tract disease in infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second such season. The companies plan to make Beyfortus available in the United States ahead of the upcoming RSV season, Sanofi said, adding that it plans to share more information about the therapy's price closer to the season. RSV is a leading cause of hospitalizations in infants and so far Swedish Orphan Biovitrum's (SOBIV.ST) treatment, Synagis, was the only approved preventive therapy in the United States for high-risk infants. The therapy comes with warnings and precautions about serious hypersensitivity reactions, and should be given with caution to infants and children with clinically significant bleeding disorders, the FDA said.
Persons: AstraZeneca's, Sanofi, Beyfortus, Bhanvi Satija, Shinjini Ganguli, Maju Samuel Organizations: U.S . Food, Drug Administration, Sanofi, American Academy of Pediatrics, FDA, Thomson Locations: U.S, United States, Bengaluru
☆ New RSV vaccines may soon put an end to rough seasons
  + stars: | 2022-10-31 | by ( Brenda Goodman | ) edition.cnn.com   time to read: +15 min
The monoclonal antibody, Synagis, is given monthly during RSV season to protect preemies and other high-risk babies. In the failed RSV vaccine trial, the chemical the researchers used to deactivate the virus denatured its proteins – essentially flattening them. Four companies have RSV vaccines for adults in the final phases of human trials: Pfizer and GSK are testing vaccines for pregnant women as well as seniors. Janssen, Pfizer and GSK each appear effective at preventing infections in adults for the first RSV season after the vaccine. The vaccines for pregnant women are meant to get newborns through their first RSV season.
☆ Why isn’t there an RSV vaccine for kids?
  + stars: | 2022-10-26 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com   time to read: +4 min
That there is no RSV vaccine for kids is not for lack of interest, experts say. But a trial gone wrong many years ago and a tricky target protein have made developing an RSV vaccine difficult. Researchers’ attempts to develop an RSV vaccine go back decades, according to Dr. Ofer Levy, the director of the Precision Vaccines Program at Boston Children's Hospital. In August, Pfizer announced that its experimental RSV vaccine was nearly 86% effective in preventing severe illness in adults ages 60 and older. GSK, however, said it abandoned its efforts last year to develop a pediatric RSV vaccine, because trials suggested it wasn't effective.
☆ Explainer: COVID, flu and RSV this U.S. winter: Why experts are worried
  + stars: | 2022-10-26 | by ( Nancy Lapid | ) www.reuters.com   time to read: +3 min
REUTERS/Carlo Allegri/File PhotoOct 26 (Reuters) - U.S. doctors are warning that a surge in cases of respiratory syncytial virus (RSV) is coinciding with an increase in COVID transmission and an earlier-than-normal flu season, raising the specter of a "tripledemic" of respiratory illness this winter. In particular, RSV infections among young children are reportedly filling some U.S. hospitals to capacity. Older children and most adults typically experience mild, cold-like symptoms. In the meantime, it is important "for everyone to get up to date on their COVID and flu vaccines," Varma said. Part of the increase in RSV cases is due to the relaxation of COVID-precautions, such as masking and social distancing, which reduced rates of both RSV and flu during the pandemic, Varma said.
☆ Surge in cases of RSV, a virus that can severely sicken infants, is filling hospital beds
  + stars: | 2022-10-15 | by ( Aria Bendix | ) www.cnbc.com   time to read: +9 min
He tested positive for respiratory syncytial virus, or RSV, a common virus that causes lung infections. Aesop was moved to a pediatric ICU on Tuesday after his heart and breathing rates soared. Many RSV patients in Massachusetts are being transferred to nearby states, she added. At Comer Children's Hospital in Chicago, hospital and ICU beds have been full for over a month. He said the volume of RSV patients is "two to three times what we've ever experienced."
☆ Surge in RSV, virus that can severely sicken infants, fills hospital beds
  + stars: | 2022-10-14 | by ( Aria Bendix | Aria Bendix Is The Breaking Health Reporter For Nbc News Digital. | ) www.nbcnews.com   time to read: +9 min
He tested positive for respiratory syncytial virus, or RSV, a common virus that causes lung infections. Aesop was moved to a pediatric ICU on Tuesday after his heart and breathing rates soared. Many RSV patients in Massachusetts are being transferred to nearby states, she added. At Comer Children’s Hospital in Chicago, hospital and ICU beds have been full for over a month. He said the volume of RSV patients is "two to three times what we’ve ever experienced."
0 next >>
Total: 8